151 related articles for article (PubMed ID: 38096681)
1. Discovery of an adjuvant that resensitizes polymyxin B-resistant bacteria.
Mahdavi M; Findlay BL
Bioorg Med Chem; 2024 Jan; 97():117541. PubMed ID: 38096681
[TBL] [Abstract][Full Text] [Related]
2. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin Combinations Combat
Bulman ZP; Chen L; Walsh TJ; Satlin MJ; Qian Y; Bulitta JB; Peloquin CA; Holden PN; Nation RL; Li J; Kreiswirth BN; Tsuji BT
mBio; 2017 Jul; 8(4):. PubMed ID: 28743810
[TBL] [Abstract][Full Text] [Related]
4. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
Kim SJ; Jo J; Kim J; Ko KS; Lee W
Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of a novel adjuvant for polymyxin B against multidrug-resistant Acinetobacter baumannii.
Kim SY; Seo HW; Park MS; Park CM; Seo J; Rho J; Myung S; Ko KS; Kim JS; Ryu CM
J Antimicrob Chemother; 2023 Apr; 78(4):923-932. PubMed ID: 36880170
[TBL] [Abstract][Full Text] [Related]
6. The use of 4-Hexylresorcinol as antibiotic adjuvant.
Nikolaev YA; Tutel'yan AV; Loiko NG; Buck J; Sidorenko SV; Lazareva I; Gostev V; Manzen'yuk OY; Shemyakin IG; Abramovich RA; Huwyler J; El'-Registan GI
PLoS One; 2020; 15(9):e0239147. PubMed ID: 32960928
[TBL] [Abstract][Full Text] [Related]
7. Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants.
Yu B; Roy Choudhury M; Yang X; Benoit SL; Womack E; Van Mouwerik Lyles K; Acharya A; Kumar A; Yang C; Pavlova A; Zhu M; Yuan Z; Gumbart JC; Boykin DW; Maier RJ; Eichenbaum Z; Wang B
ACS Infect Dis; 2022 Aug; 8(8):1491-1508. PubMed ID: 35801980
[TBL] [Abstract][Full Text] [Related]
8. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide.
Viljanen P; Vaara M
Antimicrob Agents Chemother; 1984 Jun; 25(6):701-5. PubMed ID: 6331296
[TBL] [Abstract][Full Text] [Related]
10. Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria.
Barker WT; Martin SE; Chandler CE; Nguyen TV; Harris TL; Goodell C; Melander RJ; Doi Y; Ernst RK; Melander C
Bioorg Med Chem; 2017 Oct; 25(20):5749-5753. PubMed ID: 28958847
[TBL] [Abstract][Full Text] [Related]
11. [The action of combinations of the nonapeptide polymyxin B with antibiotics on gram-negative bacteria].
Bairamashvili DI; Zinchenko AA; Maslin DN; Trakhanova MN; Miroshnikov AI
Antibiot Khimioter; 1988 Aug; 33(8):591-4. PubMed ID: 2848467
[TBL] [Abstract][Full Text] [Related]
12. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.
Ezadi F; Ardebili A; Mirnejad R
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939
[TBL] [Abstract][Full Text] [Related]
14. An Original and Efficient Antibiotic Adjuvant Strategy to Enhance the Activity of Macrolide Antibiotics against Gram-Negative Resistant Strains.
Troudi A; Bolla JM; Klibi N; Brunel JM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293314
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the ATP Synthase Eliminates the Intrinsic Resistance of
Vestergaard M; Nøhr-Meldgaard K; Bojer MS; Krogsgård Nielsen C; Meyer RL; Slavetinsky C; Peschel A; Ingmer H
mBio; 2017 Sep; 8(5):. PubMed ID: 28874470
[No Abstract] [Full Text] [Related]
16. MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in
Daly SM; Sturge CR; Felder-Scott CF; Geller BL; Greenberg DE
mBio; 2017 Nov; 8(6):. PubMed ID: 29114023
[TBL] [Abstract][Full Text] [Related]
17. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
18. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria.
Qian CD; Wu XC; Teng Y; Zhao WP; Li O; Fang SG; Huang ZH; Gao HC
Antimicrob Agents Chemother; 2012 Mar; 56(3):1458-65. PubMed ID: 22183171
[TBL] [Abstract][Full Text] [Related]
19. Breaking antimicrobial resistance by disrupting extracytoplasmic protein folding.
Furniss RCD; Kaderabkova N; Barker D; Bernal P; Maslova E; Antwi AAA; McNeil HE; Pugh HL; Dortet L; Blair JMA; Larrouy-Maumus G; McCarthy RR; Gonzalez D; Mavridou DAI
Elife; 2022 Jan; 11():. PubMed ID: 35025730
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant
Dhiman S; Ramirez D; Li Y; Kumar A; Arthur G; Schweizer F
ACS Infect Dis; 2023 Apr; 9(4):864-885. PubMed ID: 36917096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
